Amalgamated Bank Has $11.98 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Amalgamated Bank trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 7.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,513 shares of the medical device company’s stock after selling 7,732 shares during the period. Amalgamated Bank’s holdings in DexCom were worth $11,976,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Valley National Advisers Inc. lifted its position in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares during the period. MV Capital Management Inc. lifted its holdings in shares of DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares during the period. Washington Trust Advisors Inc. boosted its position in shares of DexCom by 120.6% during the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after acquiring an additional 193 shares in the last quarter. NBC Securities Inc. acquired a new stake in shares of DexCom during the 3rd quarter worth approximately $47,000. Finally, Thompson Siegel & Walmsley LLC bought a new position in DexCom in the third quarter valued at approximately $48,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Up 1.4 %

Shares of NASDAQ:DXCM traded up $1.72 during mid-day trading on Friday, reaching $128.37. 1,778,982 shares of the company’s stock were exchanged, compared to its average volume of 2,993,904. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The firm has a market capitalization of $51.05 billion, a price-to-earnings ratio of 82.82, a PEG ratio of 2.16 and a beta of 1.23. The business’s fifty day moving average price is $132.11 and its 200-day moving average price is $119.96.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. On average, research analysts predict that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other DexCom news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the sale, the executive vice president now directly owns 80,441 shares in the company, valued at $10,747,722.01. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the transaction, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. Insiders sold 190,004 shares of company stock worth $25,610,270 over the last ninety days. 0.41% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on DXCM. Raymond James raised their target price on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Canaccord Genuity Group raised their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday. UBS Group raised their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, Citigroup upped their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $141.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.